MitoRx Therapeutics announces appointments

7 March 2023
boardroom-large-1-

UK biotech MitoRx Therapeutics has announced appointments, with Christine Charman named as chief development officer, David Richardson as finance director, and four appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd Schwahn.

MitoRx) is a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases,

Christine Charman comes with close to 26 years’ experience in accelerating transformational therapies as senior global program lead for Takeda’s (TYO: 4502) rare diseases, respiratory and immunology and neuroscience therapy areas. She also worked as consultant CDO at Izana Bioscience and development consultant for a range of biotechs and newcos and program lead supporting UK Vaccine and Antiviral Task Forces, with further development experience at Novartis (NOVN: VX) from pre-clinical research leadership to senior global program Director, including the planning, clinical execution and launch of two products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology